A stronger Ozempic is coming. What to know about CagriSema, Novo Nordisk's new weight loss drug CagriSema, Novo Nordisk's Latest Obesity Drug Offering, Disappoints Investors with Trial Results Xtalks Semaglutide, Tirzepatide, Retatrutide and Cagrilintide are often lumped together, but they are not doing the same thing. : r Wegovy PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed., What is the pipeline for future medications for obesity? International Journal of Obesity